Completed PHASE2 INTERVENTIONAL 1-arm NCT04107103

Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus)

A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck

Sponsor: AHS Cancer Control Alberta

Conditions SCCHN

Interventions Combination Product: Nivolumab with Pemetrexed

Updated 6 times since 2019 Last updated: Jun 13, 2024 Started: Mar 19, 2020 Primary completion: Apr 14, 2023 Completion: Apr 28, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on SCCHN, this trial is completed. The trial is conducted by AHS Cancer Control Alberta and has accumulated 6 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jul 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Recruiting PHASE2
May 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Oct 2019 — May 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AHS Cancer Control Alberta
Alberta Cancer Foundation

Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada